



Biotech Daily

Tuesday September 1, 2020

Daily news on ASX-listed biotechnology companies

- * AUGUST BDI-40 UP 8.3%, ASX200 UP 2.2%, BIG CAPS DOWN 0.2%
- * TODAY: ASX, BIOTECH DOWN: STARPHARMA UP 12%; PROTEOMICS DOWN 9%
- * THC H1 REVENUE UP 63% TO \$3.5m, LOSS DOWN 3.2% TO \$5.6m
- * G MEDICAL H1 REVENUE DOWN 31% TO \$2.7m, LOSS DOWN 30% TO \$6.7m
- * CARDIEX REVENUE UP 13.7% TO \$4.6m, LOSS UP 11.5% TO \$3.3m
- * MGC REVENUE UP 210% TO \$2m, LOSS UP 124.6% TO \$19.4m
- * CRESO H1 REVENUE UP 58.3% TO \$1.5m, LOSS UP 177.3% TO \$17.4m
- * IMMURON REVENUE UP 5.5% TO \$2.5m, LOSS DOWN 37.1% TO \$2.9m
- * TBG H1 REVENUE UP 22.9% TO \$1.9m, PROFIT TO LOSS OF \$1.2m
- * CANN GLOBAL REVENUE UP 271% TO \$1.8m, LOSS DOWN 12.8% TO \$8.1m
- * EMERALD REVENUE UP TO \$1m, LOSS UP 95.2% TO \$5.2m
- * TELIX: IRE ELIT TO DISTRIBUTE TLX591-CDX IN FRENCH TERRITORIES
- * DORSAVI: STUDY LINKS IMPROVED LOW BACK PAIN, VIMOVE DATA
- * MEDLAB SIGNS CRO GEORGE CLINICAL FOR PHASE III NANABIS TRIALS
- * STARPHARMA: WATER-SOLUBLE DEP-REMDESIVIR FOR COVID-19
- * NOXOPHARM STARTS EAST EUROPE NOX66 COVID-19 TRIAL
- * RESAPP EXTENDS MORAYFIELD CLINIC DIAGNOSTIC EVALUATION
- * ESENSE ISRAEL TRIAL OF TERPENES FOR SARS-COV-2 SANITIZERS
- * RECCE WINS FEDERAL \$37.5k INNOVATION CONNECTIONS GRANT
- * RESPIRI: WHEEZO DETECTS 74% OF TRUE POSITIVE WHEEZES
- * PHARMAUST, OBSIDIAN PARTNER FOR WASTE TO FUELS TECH
- * BOD: LYPHE APPOINTED PROJECT TWENTY21 MARIJUANA DISPENSER
- * GENETIC TECHNOLOGIES \$22.1m REGAINS NASDAQ COMPLIANCE
- * DIMERIX 100% DIRECTOR FEE POOL HIKE AGM TO \$500k
- * FIL TAKES 6% OF STARPHARMA
- * INVION APPOINTS ROB MERRIEL DIRECTOR

MARKET REPORT

The Australian stock market fell 1.77 percent on Tuesday September 1, 2020, with the ASX200 down 107.1 points to 5,953.4 points. Ten of the Biotech Daily Top 40 stocks were up, 21 fell, eight traded unchanged and one was untraded. All three Big Caps fell.

Starpharma was the best, up 18.5 cents or 12.2 percent to \$1.70, with 9.7 million shares traded. Actinogen climbed 7.7 percent; Optiscan and Universal Biosensors were up more than three percent; Next Science, Pro Medicus and Universal Biosensors were up more than one percent; with Cynata, Kazia and Telix up by less than one percent.

Proteomics led the falls, down 5.5 cents or nine percent to 55.5 cents, with 263,599 shares traded. Amplia and Orthocell lost more than seven percent; Prescient and Uscom were down more than five percent; Antisense, Avita and LBT fell four percent or more; Dimerix and Paradigm were down more than three percent; Clinuvel, Genetic Signatures, Immutep, Impedimed and Medical Developments shed more than two percent; Cochlear, Compumedics, CSL, Imugene, Mesoblast, Neuren and Polynovo were down more than one percent; with Nanosonics and Resmed down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The last month of Southern Winter saw a complete recovery from any Covid-19 pandemic blues, with the Biotech Daily Top-40 Index (BDI-40) up 8.3 percent to a collective market capitalization of \$16,348 million, just 2.6 percent below the January 31 all-time high.

By comparison, the benchmark ASX200 was up 2.2 percent in August to 6,061 points, still 8.2 percent below August 31, 2019. The BDI-40 was up 12.9 percent for the year to August 31, 2020. The Nasdaq Biotechnology Index was up 0.9 percent in August and 31.7 percent for the year.

The three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) slipped 0.2 percent in August, but were up 19.5 percent for the year.

Most of the Big Caps loss was due to Resmed falling 13.4 percent to \$35,022 million, despite posting revenue up 13.4 percent and net profit after tax up 31.6 percent to \$962 million. Cochlear slipped half a percent to \$12,631 million, while CSL climbed 4.3 percent to \$129,960 million.

For the month of August, 23 of the BDI-40 companies were up, 17 by more than 10 percent and 11 by more than 20 percent. Seventeen fell, with six down by more than 10 percent.

Mesoblast was the largest contributor to the BDI-40 gains, up \$869 million following a successful US Food and Drug Administration committee hearing.

But the biggest percentage gain went to Kazia up 96.2 percent to \$104 million on the FDA August hat-trick of rare paediatric disease approval, fast-track designation and orphan drug designation for paxalisib, formerly known as GDC-0084, for brain cancers - proving that chief executive officer Dr James Garner, unlike his Hollywood namesake, is no (Bret) maverick.


Prescient was up \$15 million or 68.2 percent to \$37 million, followed by Dimerix (65.9%), Alterity (48.7%), Cynata (42.5%), Mesoblast (38.8%), Starpharma (37.6%), Optiscan (36.4%), Orthocell (28.1%), Telix (27.0%), Universal Biosensors (22.2%), Antisense (15.8%), Avita (15.6%), Amplia (15.4%), Pharmaxis (15.15%), and Actinogen (11.5%).

Osprey led the falls, down 30 percent to \$42 million, followed by LBT Innovations (16.3%), Uscom (13.3%), Compumedics (11.5%), Paradigm (10.8%), Resonance (10.1%) and Impedimed (9.0%).


The 22 companies that comprise Cannabis Corner were up 7.5 percent in August to \$1,146 million, but down 40.9 percent for the year, from the all-time high of \$1,939 million.

On the Nasdaq, Queensland's Protagonist jumped 42.2 percent to \$1,118 million, Redhill (with Australian assets) was up 0.8 percent to \$395 million, with Eyepoint (Psivida) down 26.6 percent to \$91 million.

BDI-40 v ASX200 Aug 31, 2006 to Aug 31, 2020- Adjusted



Five-year Big Caps \$m (Cochlear, CSL, Resmed) to Aug 31, 2020



THC (THE HYDROPONICS CO) GLOBAL GROUP

THC says revenue for the six months to June 30, 2020 was up 63.0 percent to \$3,483,566 with net loss after tax down 3.2 percent to \$5,578,924.

THC said revenue included \$3,428,003 from the manufacture and distribution of hydroponics equipment, materials and nutrients and \$55,563 from its Canndeo medical marijuana products.

The company said net tangible asset backing per share was down 7.1 percent to 13 cents, diluted loss per share was down 11.3 percent to 3.94 cents and it had cash and cash equivalents of \$9,039,348 at June 30, 2020 compared to \$5,689,612 at June 30, 2019. THC fell one cent or 4.3 percent to 22.5 cents.

G MEDICAL INNOVATIONS HOLDINGS

G Medical says revenue for the six months to June 30, 2020 was down 30.9 percent to \$US2,010,000 (\$A2,714,595) with net loss after tax down 30.4 percent to \$US4,981,000 (\$A6,727,065).

G Medical said the decrease in revenue was partly due to a drop in patients being monitored at its independent diagnostics testing facilities.

The company said revenue included \$US1,981,000 from cardiac monitoring services and \$US29,000 from diagnostic equipment products.

G Medical said net tangible asset backing per share was down 27.8 percent to negative 0.013 US cents, basic loss per share was down 52.6 percent to 0.9 US cents and it had cash and cash equivalents of \$US543,000 at June 30, 2020.

G Medical was unchanged at 4.1 cents with six million shares traded..

CARDIEX

Cardiex says revenue for the year to June 30, 2020 was up 13.7 percent to \$4,616,664 with net loss after tax up 11.5 percent to \$3,320,427.

Cardiex said revenue was from sales of cardiovascular devices and services to hospitals, clinics, research institutions and pharmaceutical companies, including \$1,895,584 from sales of goods, \$1,495,974 in lease income, \$632,099 in service income, \$132,231 in freight income, \$136,664 in royalty income and a \$324,112 fair value adjustment.

The company said net tangible asset backing per share was down 20.0 percent to 0.8 cents, diluted loss continued at 0.46 cents a share and it had cash and cash equivalents of \$2,061,642 at June 30, 2020 compared to \$4,980,826 at June 30, 2019.

Cardiex was unchanged at 5.4 cents with 3.3 million shares traded.

MGC PHARMACEUTICALS

MGC says revenue for the year to June 30, 2020 was up 210.0 percent to \$2,034,649 with net loss after tax up 124.6 percent to \$19,370,226.

MGC said the increased net loss was due to the restatement of comparative results, related to the reassessment of \$6,270,000 performance shares as an equity-based share-based payment, and revenue included \$1,119,414 in pharma sales and \$915,235 in non-pharma sales.

MGC said net tangible asset backing per share was down 54.2 percent to 0.22 cents, diluted loss per share was up 97.2 percent to 1.40 cents and it had cash and cash equivalents of \$1,873,373 at June 30, 2020 compared to \$2,354,086 at June 30, 2019.

MGC was unchanged at 2.5 cents with 8.5 million shares traded.

CRESO PHARMA

Creso says revenue for the six months to June 30, 2020 was up 58.3 percent to \$1,462,638 with net loss after tax up 177.3 percent to \$17,406,878.

Creso said revenue was from sales of its food additive and marijuana products, including \$1,196,891 from Europe and the Middle East, \$256,637 from North America and \$9,110 in royalty income.

The company said net tangible asset backing per share was down 86.7 percent to 1.6 cents, diluted loss per share was down 14.4 percent to 7.97 cents and it had cash and cash equivalents of \$3,282,130 at June 30, 2020 compared to \$3,578,130.

Creso fell 0.1 cents or 2.9 percent to 3.4 cents with 2.2 million shares traded.

IMMURON

Immuron says revenue for the year to June 30, 2020 was up 5.5 percent to \$2,518,566 with net loss after tax down 37.1 percent to \$2,927,206.

Immuron said revenue was from its cow colostrum hyperimmune products, including Travelan and Protectyn, primarily in Australia, the US and Canada.

The company said net tangible asset backing per share was down 29.6 percent to 3.17 cents, diluted loss per share was down 48.4 percent to 1.66 cents and it had cash and cash equivalents of \$3,250,468 at June 30, 2020 compared to \$5,119,887 at June 30, 2019.

Immuron fell two cents or 6.1 percent to 31 cents with 1.65 million shares traded.

TBG DIAGNOSTICS

TBG says revenue for the six months to June 30, 2020 was up 22.9 percent to \$1,915,315 with net profit turned to a loss of \$1,158,209.

TBG said revenue was from sales from its in vitro diagnostics segment, but "sales from Covid-19 test kits also contributed to the positive result", with sales revenue of \$1,787,415 and technical services revenue of \$127,900.

The company said the net loss was down due to the previous year's discontinue operations of the China group, TBG Biotechnology (Xiamen) Inc and its subsidiaries.

TBG said net tangible asset backing per share was down 28.8 percent to 4.2 cents, diluted earnings per share of 4.88 cents was turned to a loss of 0.53 cents, and it had cash and cash equivalents of \$4,098,860 at June 30, 2020 compared to \$6,920,214 at June 30, 2019.

TBG was in an ASX suspension and last traded at 27 cents (BD: Mar 19, 2020).

CANN GLOBAL

Cann Global says revenue for the year to June 30, 2020 was up 275.5 percent to \$1,805,004 with net loss after tax down 12.8 percent to \$8,050,808.

Cann Global said revenue was from its hemp and medical marijuana products, including \$1,630,532 from sales of goods and \$151,191 from services, up due to the acquisition of T12 in August 2019.

The company said net tangible asset backing per share was up 34.6 percent to 0.35 cents, diluted loss per share was down 54.4 percent to 0.26 cents and it had cash and cash equivalents of \$7,417,095 at June 30, 2020 compared to \$5,183,769 at June 30, 2019.

Cann Global was unchanged at 0.5 cents with 41.9 million shares traded.

EMERALD CLINICS

Emerald says revenue for the year to June 30, 2020 was up nine-fold to \$1,013,452 with net loss after tax up 95.2 percent to \$5,238,040.

Emerald said revenue was from its specialist marijuana clinics and from the collection of real-world evidence data.

The company said net tangible asset backing per share was up 442.1 percent to 2.06 cents, diluted loss per share was up 47.6 percent to 3.04 cents and it had cash and cash equivalents of \$3,686,333 at June 30, 2020 compared to \$2,608,814 at June 30, 2019.

Emerald was up half a cent or 5.9 percent to nine cents.

TELIX PHARMACEUTICALS

Telix says the Fleurus, Belgium-based Ire Elit SA will distribute its prostate cancer imaging product TLX591-CDx in France and French overseas territories.

Telix said Ire would be the exclusive distributor for both the initial temporary authorization period and following European marketing authorization, expected in 2021.

Telix was up one cent or 0.6 percent to \$1.66.

DORSAVI

Dorsavi says a study by Curtin University researchers has shown a link between its Vimove sensors and improvement of low back pain.

Dorsavi said the paper, titled 'Movement, posture and low back pain. How do they relate?', was published in the European Journal of Pain.

The company said the study assessed 12 people with persistent and disabling low back pain, using movement metrics and muscle activity analysis.

Dorsavi said the authors of the study said that 57 of 61 (93.4%) of relationships observed between clinical improvement and Vimove data, related to increased movement range and velocity during forward bending and lifting, reduced lumbar muscle electromyography (EMG) activity at maximum voluntary flexion, and increased posterior-pelvic-tilt during sitting and standing.

The company said the finding was important because clinical improvement in low back pain was statistically related to a change in objective metrics captured by wearable sensors.

Dorsavi was up 0.1 cents or 4.55 percent to 2.3 cents with 1.4 million shares traded.

MEDLAB CLINICAL

Medlab says it has a contract research organization agreement with Sydney's George Clinical to support its phase III trials of Nanabis for cancer-induced bone pain.

Medlab said George Clinical would provide site selection, feasibility, trial recruitment and ongoing site management for US trial sites and would implement the data service for all phase III sites.

The company said the trials followed a phase I/II study completed at Sydney's Royal North Shore Hospital this year.

Medlab fell half a cent or 3.2 percent to 15 cents.

STARPHARMA

Starpharma says it has applied its dendrimer enhanced product (DEP) technology to develop a long-acting, water soluble version of remdesivir, also known as Veklury. Starpharma said that remdesivir was a broad-spectrum antiviral drug, currently being developed by the Foster City, California-based Gilead Sciences to treat Covid-19.

Last week, Gilead said the US Food and Drug Administration had expanded the emergency use authorization to treat all hospitalized patients with Covid-19, in addition to the previous authorization for patients hospitalized with severe Covid-19.

Gilead said the expansion was based on phase III data on patients with moderate Covid-19 pneumonia, as well as a National Institute of Allergy and Infectious Diseases trial.

Gilead said patients randomized to a 5-day course of Veklury plus standard-of-care were 65 percent more likely to have improved clinical status compared with those randomized to standard-of-care alone ($p = 0.017$), but for those on 10-day treatment, improvement “was not statistically different compared with the standard-of-care group” ($p = 0.183$).

Today, Starpharma said that its DEP slow release version “could be administered subcutaneously rather than by intravenous infusion in hospital ... [and had] improved pharmacokinetics”.

The company said its version “would potentially allow for less frequent dosing and use in a non-hospital setting, such as aged-care” as well as outpatient treatment.

Starpharma chief executive officer Dr Jackie Fairley said that “given the limited treatment options available for Covid-19 patients, Starpharma has been actively reviewing development programs globally, and evaluating where Starpharma’s proprietary DEP technology has potential to improve delivery, expand use or reduce frequency of dosing”.

“The ability to deliver remdesivir via a long-acting, subcutaneous injection has the potential to expand its application outside hospitals, into settings like aged care, and also facilitate its use in countries with less developed healthcare systems,” Dr Fairley said.

Dr Fairley said the program was separate to the development of SPL7013 for Covid-19.

Starpharma was up 18.5 cents or 12.2 percent to \$1.70 with 9.7 million shares traded.

NOXOPHARM

Noxopharm says it has begun a 40-patient, phase I trial of its cancer treatment Veyonda, for Covid-19 in the Ukraine and Moldova (BD: Apr 1, 2020).

Noxopharm said the trial was “an important medical milestone” as it was the first known use of a drug in Covid-19 patients that inhibited the stimulator of interferon genes, or Sting, pathway which the company said was “increasingly being incriminated as a leading cause of death and long-term disability in these patients”.

Noxopharm said that Veyonda, also known as NOX66 or idronoxil, was being trialled in the Eastern European countries which had high rates of infection and hospitalization.

The company said that a range of doses would be given to patients hospitalized with moderate symptoms and were “at high risk of tipping over into a cytokine storm and developing septic shock”.

Noxopharm said that patients will be treated with Veyonda for at least 14 days and may receive treatment for up to 28 days if required.

The company said the trial would measure safety and tolerability in patients with poor lung function, “as well as the drug’s ability to prevent patients progressing into a cytokine storm and septic shock” with one key endpoint the effect of treatment on blood cytokine levels.

Noxopharm said that patients would be enrolled until late-October 2020 with results expected in early-2021.

Noxopharm was up one cent or 3.3 percent to 31.5 cents with 1.3 million shares traded.

RESAPP HEALTH

Resapp says it has extended its free use of its Resappdx smartphone-based respiratory diagnostic test at Health Hub Doctors Morayfield in Queensland.

In May, Resapp said the Resappdx-EU was under evaluation at the clinic and today said it had extended the free licence for a further three months (BD: May 11, 2020)

The company said the clinic was “one of the first respiratory clinics established with Federal Government funding to take pressure off local hospitals by treating mild-moderate respiratory illnesses and assessing patients requiring Covid-19 testing”.

Resapp said the mobile telephone-based diagnostic was being used “to triage patients” to help identify illnesses such as lower respiratory tract infections, pneumonia, asthma exacerbations and chronic obstructive pulmonary disease exacerbations.

Resapp was unchanged at 12 cents with 1.5 million shares traded.

ESENSE-LAB

Esense says it has Israeli approval to test its terpene compounds as sanitizers against severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2).

Previously, Esense said that it was developing its marijuana terpenes for use in chocolate and beer as well as for “vaping” (BD: Nov 16, Dec 12, 2017; Jun 6, 2018).

Today, the company said it would begin “a joint research project at ... the Chaim Sheba Medical Center for testing of its proprietary TRP-ENV compound”.

Esense said it had a research agreement with the Israeli Ministry of Health to test TRP-ENV against the human coronavirus strain OC43, “as a model for Sars-Cov-2, and would provide further research into terpenes’ anti-viral qualities to reduce the ethanol content in sanitizers”.

The company said the research covered 16 formulations infused with TRP-ENV alone and in combinations with other active ingredients to determine their efficacy over various virus incubation times and their effectiveness on a range of surfaces.

Esense was untraded at 1.8 cents.

RECCE PHARMACEUTICALS

Recce says it has received a \$37,508 Federal Government Entrepreneurs’ Program Innovation Connections grant.

Recce said it would use the grant funds for project costs to assess Recce-327 for severe acute respiratory syndrome-coronavirus-2 (Sars-Cov-2).

Recce said it would receive an up to \$50,000 follow up grant upon completion of performance milestones.

Recce was up 6.5 cents or 4.4 percent to \$1.535 with 1.1 million shares traded.

RESPIRI

Respiri says a 56-patient study of 114 asthma wheeze recordings shows its Wheezo detects 74 percent of true wheezes and 83 percent of no wheezes.

Respiri said the study assessed wheeze severity in patients admitted with an exacerbation of airway disease with clinically detectable wheeze, compared to physician assessments.

The company said that when compared to a physician assessment, its device detected a true positive in 81 percent of cases and no wheeze in 79 percent of cases.

Respiri was up half a cent or 3.2 percent to 16 cents with 2.5 million shares traded.

PHARMAUST

Pharmaust says wholly owned subsidiary Epichem and Western Australia's Obsidian Minerals have established Perren Pty Ltd to develop a waste to fuels technology. Pharmaust said both companies would own 50 percent of Perren, with Epichem chief executive officer Colin La Galia appointed as the chief executive officer. Pharmaust was up half a cent or 2.7 percent to 19 cents with 2.9 million shares traded.

BOD AUSTRALIA

Bod says it has appointed London's Lyphe Group, as its preferred dispenser for Project Twenty21, a European medical marijuana registry with 20,000 patients. Bod fell one cent or 3.3 percent to 29 cents.

GENETIC TECHNOLOGIES

Genetic Technologies says that by raising \$US16.37 million (\$A22.10 million), it has reached the required \$US2.5 million for continued listing on the Nasdaq. Genetic Technologies said it had regained compliance and the Nasdaq Capital Market had closed its review (BD: May 3, 2019; Mar 16, May 18, 2020). Genetic Technologies was unchanged at one cent with 10.6 million shares traded.

DIMERIX

Dimerix says its annual general meeting will vote to increase its non-executive director remuneration fees pool by 100 percent to \$500,000. Dimerix said all other resolutions related to the ratification of the prior issue of placement shares and options, the adoption of its remuneration report, the 10 percent placement capacity, to adopt a new constitution and re-elect director Dr James Williams. The meeting will be held at its office at 425 Smith Street, Fitzroy, Victoria and on-line on September 30, 2020 at 11am (AEST). Dimerix fell 2.5 cents or 3.4 percent to 71.5 cents with 1.8 million shares traded.

STARPHARMA HOLDINGS

Fidelity International Limited (FIL) says it has increased its substantial shareholding in Starpharma from 18,632,740 shares (5.00%) to 22,413,859 shares (6.02%). The Sydney and Hong Kong-based FIL said that between June 19 and August 27, 2020 it bought 3,781,119 shares at prices from \$1.085 to \$1.4739 a share.

INVION

Invion says it has appointed Rob Merriel as a non-executive director, replacing Melanie Farris, effective from August 31, 2020. Invion said Mr Merriel had more than 35 years' experience, including as the chief financial officer, chief commercialization officer and company secretary for the Hudson Institute of Medical Research, and previously worked with the Baker Institute, Melbourne Health, Southern Health, Pacific Dunlop and Deloitte Consulting. Invion said Mr Merriel was a director of two biotechnology start-up companies, and had been a director of two venture capital funds. Invion was unchanged at 1.1 cents.

Biotech Daily Top 40 with Market Capitalization At August 31, 2020

Company \$Am	Sep-19	Aug-20	Sep-20
Cochlear	12,325	12,691	12,631
CSL	106,710	124,614	129,960
Resmed	29,579	40,658	35,022
BDI-20			
Avita	852	652	754
Clinuvel	1,252	1,107	1,027
Compumedics	128	78	69
Cyclopharm	93	119	111
Cynata	163	73	104
Ellex	85	47	45
Genetic Signatures	109	349	325
Immutep	81	88	95
Medical Developments	314	397	389
Mesoblast	733	2,237	3,106
Nanosonics	1,911	1,960	1,822
Neuren	190	148	146
Opthea	837	646	703
Paradigm	308	719	641
Pharmaxis	73	33	38
Polynovo	1,388	1,507	1,461
Pro Medicus	3,840	2,507	2,697
Starpharma	409	410	564
Telix	345	330	419
Volpara	318	334	346
Second 20			
Actinogen	9	26	29
Alterity (Prana)	23	39	58
Amplia (Innate)	5	13	15
Antisense	21	38	44
Dimerix	16	88	146
Impedimed	68	78	71
Imugene	76	255	241
Kazia	24	53	104
LBT Innovations	24	43	36
Next Science	474	243	240
Oncosil	45	91	95
Optiscan	20	22	30
Orthocell	63	64	82
Osprey	21	60	42
Patrys	25	15	17
Prescient	17	22	37
Proteomics	22	54	56
Resonance	47	69	62
Universal Biosensors	38	45	55
Uscom	15	30	26

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear, Cynata, Mesoblast, Nanosonics, Neuren, Patrys, Polynovo, Telix, Volpara and non-biotech stocks. Through Australian Ethical Superannuation he has an indirect interest in other companies: <https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/>. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily